U.S. Markets open in 1 hr 47 mins

Acceleron Pharma Inc. (XLRN)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
26.14+0.75 (+2.95%)
At close: 4:00PM EDT
People also watch
EPZMMGNXAGIOOMEDFPRX

Acceleron Pharma Inc.

128 Sidney Street
Cambridge, MA 02139
United States
617-649-9200
http://www.acceleronpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees121

Key Executives

NameTitlePayExercisedAge
Mr. Habib J. DableChief Exec. Officer, Pres and Director472.76kN/A48
Dr. Thomas P. Maniatis Ph.D.Co-Founder, Chairman of Scientific Advisory Board and Director40kN/A74
Mr. Kevin F. McLaughlinChief Financial Officer, Sr. VP and Treasurer522.36k608.21k61
Dr. Ravindra Kumar Ph.D.Chief Scientific Officer and Sr. VP486.25k1.37M57
Dr. Matthew L. Sherman M.D.Chief Medical Officer and Exec. VP605.43k1.38M61
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The company’s therapeutic candidates also include Dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Acceleron Pharma Inc.’s ISS Governance QualityScore as of May 1, 2017 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.